Orchid Pharma (LUX:ORCHP) LT-Debt-to-Total-Asset: 0.17 (As of Mar. 2026)

What is Orchid Pharma LT-Debt-to-Total-Asset?

Orchid Pharma LUX:ORCHP 66 LT-Debt-to-Total-Asset is 0.17 as of Mar. 2026. GuruFocus rates LUX:ORCHP with a GF Score™ of 66/100 and a GF Value™ of $4.68. The stock has 10 warning signs investors should review.

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Orchid Pharma's long-term debt to total assests ratio for the quarter that ended in Mar. 2026 was 0.17.

Orchid Pharma's long-term debt to total assets ratio increased from Mar. 2025 (0.08) to Mar. 2026 (0.17). It may suggest that Orchid Pharma is progressively becoming more dependent on debt to grow their business.

Orchid Pharma (LUX:ORCHP) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Orchid Pharma LT-Debt-to-Total-Asset Related Terms

Orchid Pharma LT-Debt-to-Total-Asset Historical Data

* Premium members only.

The historical data trend for Orchid Pharma's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Orchid Pharma LT-Debt-to-Total-Asset Chart

Orchid Pharma Annual Data

Trend

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Mar24

Mar25

Mar26

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.19

0.12

0.08

0.17

Orchid Pharma Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															0.08	0.00	0.14	0.00	0.17

66GF Score

Orchid Pharma Ltd LUX:ORCHP

LT-Debt-to-Total-Asset is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Orchid Pharma LT-Debt-to-Total-Asset Calculation

Orchid Pharma's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Mar. 2026 is calculated as

LT Debt to Total Assets (A: Mar. 2026 )	=	Long-Term Debt & Capital Lease Obligation (A: Mar. 2026 )	/	Total Assets (A: Mar. 2026 )
	=	35.818	/	205.877
	=	0.17

Orchid Pharma's Long-Term Debt to Total Asset Ratio for the quarter that ended in Mar. 2026 is calculated as

LT Debt to Total Assets (Q: Mar. 2026 )	=	Long-Term Debt & Capital Lease Obligation (Q: Mar. 2026 )	/	Total Assets (Q: Mar. 2026 )
	=	35.818	/	205.877
	=	0.17

Frequently Asked Questions Learn more about LT-Debt-to-Total-Asset →

What does a LT-Debt-to-Total-Asset of 0.17 mean?

Orchid Pharma (LUX:ORCHP) has a LT-Debt-to-Total-Asset of 0.17 as of Mar. 2026. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Orchid Pharma and its competitors.

Is Orchid Pharma's LT-Debt-to-Total-Asset too high?

Orchid Pharma's current LT-Debt-to-Total-Asset is 0.17. Overall, Orchid Pharma has a GF Score™ of 66/100, reflecting its overall financial health beyond just this single metric.

How does Orchid Pharma's LT-Debt-to-Total-Asset compare to ZTS and UTHR?

Orchid Pharma's LT-Debt-to-Total-Asset of 0.17 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good LT-Debt-to-Total-Asset for a Drug Manufacturers company?

A good LT-Debt-to-Total-Asset depends on the Drug Manufacturers industry context. However, LT-Debt-to-Total-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high LT-Debt-to-Total-Asset mean?

A high LT-Debt-to-Total-Asset can signal that a stock is expensive relative to its fundamentals. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Orchid Pharma and its competitors. Orchid Pharma's current LT-Debt-to-Total-Asset is 0.17. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Orchid Pharma stock overvalued right now?

Orchid Pharma (LUX:ORCHP) has a current LT-Debt-to-Total-Asset of 0.17. The stock's GF Value™ is $4.68, compared to a current price of $5.45 — trading 16.5% above its estimated fair value. The current LT-Debt-to-Total-Asset is 0.17. Orchid Pharma's overall GF Score™ is 66/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is LT-Debt-to-Total-Asset calculated?

LT-Debt-to-Total-Asset is calculated from a company's financial statements. For Orchid Pharma (LUX:ORCHP), the current LT-Debt-to-Total-Asset is 0.17 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Orchid Pharma (LUX:ORCHP) Overvalued in 2026?

Based on GuruFocus' analysis, Orchid Pharma stock appears to be overvalued. The current stock price of $5.45 is trading 16.5% above its estimated GF Value™ of $4.68.

Key valuation signals for LUX:ORCHP:

LT-Debt-to-Total-Asset: 0.17
GF Value™: $4.68 vs. price of $5.45 (16.5% above fair value)
GF Score™: 66/100 with 10 warning signs

No single metric tells the full story. See the LUX:ORCHP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Orchid Pharma Business Description

Industry Healthcare Drug Manufacturers

Comparable Companies BOM:506197 NSE:INNOVACAP BOM:506879 BOM:524164 NSE:RPGLIFE BOM:509079 BOM:500672 BOM:543748 BOM:524348 BOM:531599 XTER:MRK XSWX:GALD TSE:4502 SHSE:600276 NSE:SUNPHARMA LSE:HLN XTAE:TEVA XSWX:SDZ ZTS UTHR

Other Exchanges ORCHPHARMA:India 524372:India

Address Sector 74A, 15th Floor, Tower-1, DLF Corporate Greens, Narsinghpur, Gurugram, HR, IND, 122004

Website https://www.orchidpharma.com

Orchid Pharma Ltd is involved in the development, manufacturing, and marketing of diverse bulk actives, formulations, and nutraceuticals. The company operates in one business segment, which is Pharmaceuticals, in which the company derives its maximum sales through Active Pharmaceutical Ingredients. It produces various products such as tablets, injectables, and APIs for cardiovascular, anti-diabetic, neuropsychiatry, veterinary, non-antibiotic, and cephalosporins. The products are grouped under formulations and active pharmaceutical ingredients. Geographically, the company generates maximum revenue from the export of its products to international markets like the United States, Canada, Europe, Japan, Australia, and China etc., and the rest from its business in India.

66GF Score

Get the complete analysis for LUX:ORCHP

LT-Debt-to-Total-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$5.45

Price

$4.68

GF Value

View LUX:ORCHP Analysis

See LT-Debt-to-Total-Asset data for all stocks →